They Just Don't Get...
Provectus Pharmaceutical Inc. (PVCT: OTC)
$0.91 -0.02 | -2.15%
02/09/12 - 03:59 PM ET
90.53K / 150.10K
Vol / Avg. Vol:0.93 / 0.93
Open / Prev. Close:0.90 - 0.93
Today's Range:0.67 - 1.23
52 Wk Range:12.35%
Performance YTD:TheStreet Rating:
Portfolios with PVCT
- Portfolio NameUser Type
- UserPINOCH
Latest PVCT Headlines from TheStreet
- Thursday's Small-Cap Winners & Losers 09.06.07 | 03:09 pm
Press Releases for PVCT
- Provectus Receives Guidance From FDA On Pathway To Approval For Phase 3 Trial Of PV-10 For Metastatic Melanoma - Business Wire 01.18.12 | 06:01 am
- PV-10 Mechanism Of Action Data To Be Presented At The Society Of Surgical Oncology Annual Meeting March 21-24, 2012 In Orlando, Florida - Business Wire 01.17.12 | 04:01 pm
- Provectus Pharmaceuticals Will Present At The Noble Financial Capital Markets’ Eighth Annual Equity Conference On January 18, 2012 - Business Wire 01.17.12 | 04:01 pm
- Provectus Pharmaceuticals, Inc. And Its Subsidiaries Complete Unregistered Offering Of Units To Facilitate Spin-off Of Pure-ific Corporation - Business Wire 12.20.11 | 07:12 am
- Provectus Reports On Third End-of-Phase 2 Meeting With U.S. FDA To Define Pathway To Approval Of PV-10 For Metastatic Melanoma - Business Wire 11.29.11 | 06:11 am
- Data On Provectus’s PV-10 For Metastatic Melanoma Presented At The 2011 International Melanoma Congress - Business Wire 11.14.11 | 11:11 am
- Emerging Biotech Companies Discuss What’s In The Pipeline At NYSSA Conference - Business Wire 11.10.11 | 10:11 am
- Phase 2 Data On Provectus’s PV-10 For Metastatic Melanoma Will Be Presented At The 2011 International Melanoma Congress On November 12, 2011 - Business Wire 11.10.11 | 06:11 am
- Provectus Pharmaceuticals, Inc. To Present At “2nd Annual Cancer Immunotherapy: A Long-Awaited Reality” Conference On October 6, 2011 - Business Wire 09.28.11 | 06:09 am
- Provectus Pharmaceuticals Will Present At The Rodman & Renshaw 13th Annual Healthcare Conference On September 13, 2011 - Business Wire 08.31.11 | 06:08 am







